Alpha Tau Medical Ltd (DRTS)
NASDAQ:DRTS
Want to see DRTS full AI Analyst Report?
Top Page
Alpha Tau Medical Ltd
(NASDAQ:DRTS)
Select Model
Select Model
Rating:53Neutral
Price Target:
$10.50
â–²(30.76% Upside)
Action:Reiterated
Date:06/04/26
The score is held back primarily by weak financial performance (no revenue, widening losses, and increasing cash burn), partially offset by a relatively constructive technical setup (price above key moving averages with positive MACD). Valuation is also constrained by negative earnings and the absence of a dividend in the provided data.
Positive Factors
Long-term U.S. commercialization partnership
A 20-year exclusive U.S. commercialization deal with Tolmar plus an immediate $20M equity investment and $15M toward U.S. manufacturing materially de-risks Alpha Tau's U.S. market entry. The agreement provides strategic capital, production funding and a scaled commercial platform, improving odds of durable market access and faster adoption.
Negative Factors
No product revenue to date
Sustained zero revenue means the business remains wholly reliant on development milestones and partnerships rather than recurring sales. Over a multi‑month horizon, absent commercial receipts the company must fund operations externally, which increases execution risk and limits ability to self-finance commercialization and scale infrastructure.
Read all positive and negative factors
Positive Factors
Negative Factors
Long-term U.S. commercialization partnership
A 20-year exclusive U.S. commercialization deal with Tolmar plus an immediate $20M equity investment and $15M toward U.S. manufacturing materially de-risks Alpha Tau's U.S. market entry. The agreement provides strategic capital, production funding and a scaled commercial platform, improving odds of durable market access and faster adoption.
Read all positive factors
Alpha Tau Medical Ltd (DRTS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$931.14M
Dividend YieldN/A
Average Volume (3M)912.31K
Price to Earnings (P/E)―
Beta (1Y)0.84
Revenue GrowthN/A
EPS Growth-42.64%
CountryUS
Employees125
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.53
Shares Outstanding88,009,735
10 Day Avg. Volume1,043,133
30 Day Avg. Volume912,310
Financial Highlights & Ratios
PEG Ratio-0.53
Price to Book (P/B)5.17
Price to Sales (P/S)0.00
P/FCF Ratio-12.18
Enterprise Value/Market Cap1.03
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-22.75
Forecast
1Y Price Target
$12.60Price Target Upside56.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.62
Revenue Forecast (FY)$1.23M
Alpha Tau Medical Ltd Business Overview & Revenue Model
Company Description
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United S...
How the Company Makes Money
Alpha Tau Medical is a clinical-stage company and, based on publicly available information, does not have a material, broadly commercialized product revenue stream. Its cash inflows have primarily come from financing activities (e.g., proceeds fro...
Alpha Tau Medical Ltd Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
64
Positive
Cash Flow
23
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.23M | -1.10M | -1.07M | -979.00K | -776.00K |
| EBITDA | -41.06M | -30.30M | -28.03M | -32.74M | -13.21M |
| Net Income | -42.63M | -31.75M | -29.16M | -33.76M | -27.27M |
Balance Sheet | |||||
| Total Assets | 106.58M | 86.20M | 107.39M | 120.15M | 42.22M |
| Cash, Cash Equivalents and Short-Term Investments | 76.90M | 59.60M | 81.79M | 104.53M | 31.32M |
| Total Debt | 13.73M | 12.54M | 13.28M | 5.19M | 53.96M |
| Total Liabilities | 29.48M | 23.54M | 22.91M | 14.49M | 76.99M |
| Stockholders Equity | 77.10M | 62.67M | 84.47M | 105.66M | -34.78M |
Cash Flow | |||||
| Free Cash Flow | -32.76M | -22.02M | -24.36M | -24.78M | -14.74M |
| Operating Cash Flow | -26.68M | -19.78M | -17.96M | -23.88M | -11.81M |
| Investing Cash Flow | -20.59M | 20.77M | 18.68M | -89.94M | 19.27M |
| Financing Cash Flow | 45.77M | 25.00K | 5.30M | 96.91M | 111.00K |
Alpha Tau Medical Ltd Technical Analysis
Positive
8.03
Price Trends
8.53
Positive
7.88
Positive
6.02
Positive
Market Momentum
0.47
Positive
55.07
Neutral
43.09
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DRTS, the sentiment is Positive. The current price of 8.03 is below the 20-day moving average (MA) of 10.05, below the 50-day MA of 8.53, and above the 200-day MA of 6.02, indicating a bullish trend. The MACD of 0.47 indicates Positive momentum. The RSI at 55.07 is Neutral, neither overbought nor oversold. The STOCH value of 43.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DRTS.
Alpha Tau Medical Ltd Risk Analysis
Alpha Tau Medical Ltd disclosed 81 risk factors in its most recent earnings report. Alpha Tau Medical Ltd reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Alpha Tau Medical Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $931.14M | -16.23 | -73.23% | ― | ― | -42.64% | |
52 Neutral | $711.30M | -4.08 | -78.12% | ― | ― | 7.21% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $1.60B | -14.01 | -59.27% | ― | -100.00% | -62.96% | |
47 Neutral | $332.43M | -1.69 | -134.14% | ― | ― | -39.31% | |
47 Neutral | $353.35M | -4.43 | -47.48% | ― | ― | 56.00% | |
44 Neutral | $357.29M | -11.16 | -34.82% | ― | ― | 41.21% |
* Healthcare Sector Average
DRTS
Alpha Tau Medical Ltd
10.29
7.48
266.19%
LRMR
Larimar Therapeutics
3.29
0.83
33.74%
CAPR
Capricor Therapeutics
27.95
14.77
112.06%
BNTC
Benitec Biopharma
11.05
-4.12
-27.16%
AURA
Aura Biosciences Inc
6.80
0.70
11.48%
LXEO
Lexeo Therapeutics, Inc.
4.78
1.51
46.18%
Alpha Tau Medical Ltd Corporate Events
Alpha Tau Strikes 20-Year U.S. Prostate Cancer Commercialization and $20 Million Equity Deal With Tolmar
Jun 3, 2026
On June 2, 2026, Alpha Tau Medical Ltd. and its U.S. subsidiary signed a long-term collaboration and supply deal with Tolmar International Ltd., giving Tolmar exclusive rights to commercialize Alpha DaRT for prostate cancer in the United States. T...
Alpha Tau Posts Strong Pancreatic Cancer Survival Data for Alpha DaRT at 2026 ASCO
Jun 1, 2026
On June 1, 2026, Alpha Tau reported positive overall survival and safety data from a pooled analysis of three Phase I/II trials of its endoscopic ultrasound-guided Alpha DaRT treatment in patients with locally advanced or metastatic pancreatic duc...
Alpha Tau Medical Sets June 23, 2026 Shareholder Meeting to Vote on Governance and Executive Pay
May 18, 2026
Alpha Tau Medical Ltd. has convened its 2026 annual general meeting of shareholders for June 23, 2026 in Jerusalem, with a record date of May 12, 2026, and has distributed a notice, proxy statement and proxy card to investors. The meeting agenda c...
Alpha Tau Medical Posts Strong Q1 2026 Trial Progress and Completes Enrollment in First U.S. Pivotal Study
May 18, 2026
In the first quarter of 2026, Alpha Tau Medical reported that interim data from its U.S. REGAIN trial in recurrent glioblastoma, as of May 3, showed 100% local disease control and a 67% complete response rate in the first three patients, alongside...
Alpha Tau Medical Shares Interim U.S. Glioblastoma Trial Data for Alpha DaRT
May 11, 2026
On May 11, 2026, Alpha Tau Medical presented interim clinical data from its U.S. REGAIN trial of Alpha DaRT in patients with recurrent glioblastoma during a conference call and webcast, and simultaneously posted the accompanying slide deck on its ...
Alpha Tau Posts Strong Interim REGAIN Data in U.S. Recurrent Glioblastoma Trial
May 11, 2026
Alpha Tau Medical Ltd. reported on May 11, 2026, interim data from its U.S. REGAIN trial of Alpha DaRT in recurrent glioblastoma, a highly lethal and treatment-resistant brain cancer. The first three patients, treated between December 2025 and Mar...
Alpha Tau Completes Enrollment in Pivotal U.S. Skin Cancer Trial for Alpha DaRT
May 8, 2026
Alpha Tau Medical Ltd., developer of the Alpha DaRT intratumoral alpha-radiation therapy for solid tumors, is building its oncology franchise around hard‑to‑treat cancers where surgery and conventional treatments have failed. The compa...
Alpha Tau to Review Interim Data from First REGAIN Glioblastoma Patients
May 8, 2026
On May 8, 2026, Alpha Tau Medical filed a Form 6-K noting a press release about its Alpha DaRT technology and ongoing clinical efforts in difficult-to-treat cancers. The company, listed on Nasdaq under tickers DRTS and DRTSW, continues to position...
Alpha Tau Treats First Italian Pancreatic Cancer Patient With Alpha DaRT in Verona Study
May 7, 2026
On May 7, 2026, Alpha Tau Medical announced it had successfully treated the first pancreatic cancer patient in Italy with its Alpha DaRT therapy at the University of Verona’s Pancreas Institute, in a feasibility and safety study for locally ...
Alpha Tau to Present Alpha DaRT–Pembrolizumab Head and Neck Cancer Data at AHNS 2026
May 5, 2026
Alpha Tau Medical Ltd., developer of the Alpha DaRT intratumoral alpha-radiation cancer therapy, reported on May 5, 2026 that its abstract on combining Alpha DaRT with pembrolizumab in elderly patients with locally advanced and metastatic head and...
Alpha Tau Reports 100% Local Disease Control in Alpha DaRT Pancreatic Cancer Trials Presented at DDW 2026
May 4, 2026
On May 4, 2026, Alpha Tau Medical reported updated pooled data from two first-in-human trials of its Alpha DaRT therapy in pancreatic ductal adenocarcinoma, presented at the Digestive Disease Week 2026 conference. Across 19 evaluable patients with...
Alpha Tau to Present Pooled Pancreatic Cancer Alpha DaRT Data at 2026 ASCO Meeting
Apr 27, 2026
On April 27, 2026, Alpha Tau Medical announced that an abstract detailing combined safety and efficacy results from three clinical studies of its Alpha DaRT therapy in advanced pancreatic cancer has been accepted for presentation at the 2026 Ameri...
Alpha Tau Treats First European Pancreatic Cancer Patient With Alpha DaRT in ACAPELLA Trial
Apr 23, 2026
On April 23, 2026, Alpha Tau Medical announced that it has successfully treated the first European pancreatic cancer patient with its Alpha DaRT therapy in the ACAPELLA multicenter trial in France. The study targets inoperable locally advanced pan...
Alpha Tau Wins First DDW Oral Slot for Alpha DaRT Pancreatic Cancer Data
Mar 31, 2026
On March 31, 2026, Alpha Tau Medical announced that clinical data from two first-in-human pancreatic cancer trials of its Alpha DaRT therapy, conducted at Hadassah Medical Center in Jerusalem, were accepted for the company’s first-ever oral ...
Alpha Tau Posts Wider 2025 Loss as Japanese Approval and U.S. Trial Progress Mark Pivotal Year
Mar 9, 2026
Alpha Tau Medical Ltd., the developer of the Alpha DaRT alpha-radiation cancer therapy, reported its full-year 2025 results on March 9, 2026, alongside a broad clinical and regulatory update. The company is expanding into major cancer indications ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.